{"transactions":[{"id":1114572,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-11T20:05:13.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on June 10, 2026."}],"balance_after":30000,"derivative":{"exercise_price":0.33,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001641172-25-014695","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614936/000164117225014695/ownership.xml","form_type":"4"}},{"id":1173133,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T20:15:22.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250,"price":0.5,"value":125.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":355.2,"exercise_date":"2018-06-28","expiration_date":"2025-06-28","underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001641172-25-003825","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1614936/000164117225003825/ownership.xml","form_type":"4"}},{"id":1173132,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T20:15:22.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250,"price":0.5,"value":125.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":388.64,"exercise_date":"2019-06-28","expiration_date":"2026-06-28","underlying":"Common Stock","underlying_shares":250},"source":{"system":"sec-edgar","filing":"0001641172-25-003825","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1614936/000164117225003825/ownership.xml","form_type":"4"}},{"id":1173131,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T20:15:22.000Z","date":"2025-04-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":500,"price":0.5,"value":250.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The options were canceled by mutual agreement of the reporting person and Indaptus Therapeutics, Inc. The reporting person received $500 total as consideration for the cancellation."}],"balance_after":0,"derivative":{"exercise_price":24.6,"exercise_date":"2020-07-15","expiration_date":"2027-07-15","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0001641172-25-003825","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614936/000164117225003825/ownership.xml","form_type":"4"}},{"id":1349896,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-11-27T16:06:38.000Z","date":"2024-11-25","kind":"exercise","planned":false,"acquired":false,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25, and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25, and November 25 of each year."}],"balance_after":18069,"derivative":{"underlying":"Common Stock","underlying_shares":9034},"source":{"system":"sec-edgar","filing":"0000950170-24-131475","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024131475/ownership.xml","form_type":"4"}},{"id":1349895,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-27T16:06:38.000Z","date":"2024-11-25","kind":"exercise","planned":false,"acquired":true,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":126478,"source":{"system":"sec-edgar","filing":"0000950170-24-131475","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024131475/ownership.xml","form_type":"4"}},{"id":1409055,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-09-12T18:10:04.000Z","date":"2024-08-25","kind":"exercise","planned":false,"acquired":false,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":27103,"derivative":{"underlying":"Common Stock","underlying_shares":9034},"source":{"system":"sec-edgar","filing":"0000950170-24-106026","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024106026/ownership.xml","form_type":"4"}},{"id":1409054,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-12T18:10:04.000Z","date":"2024-08-25","kind":"exercise","planned":false,"acquired":true,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":117444,"source":{"system":"sec-edgar","filing":"0000950170-24-106026","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024106026/ownership.xml","form_type":"4"}},{"id":1471087,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-24T19:40:56.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date."}],"balance_after":18750,"derivative":{"exercise_price":0.569,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":18750},"source":{"system":"sec-edgar","filing":"0000950170-24-076990","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024076990/ownership.xml","form_type":"4"}},{"id":1471086,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-24T19:40:56.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date."}],"balance_after":50000,"derivative":{"exercise_price":0.569,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-24-076990","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024076990/ownership.xml","form_type":"4"}},{"id":1486122,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T21:00:14.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on June 6, 2025."}],"balance_after":30000,"derivative":{"exercise_price":2.63,"expiration_date":"2034-06-06","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-24-023149","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614936/000149315224023149/ownership.xml","form_type":"4"}},{"id":1499473,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-05-29T19:12:33.000Z","date":"2024-05-25","kind":"exercise","planned":false,"acquired":false,"shares":9035,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25, and November 25 of each year."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25, and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25, and November 25 of each year."}],"balance_after":36137,"derivative":{"underlying":"Common Stock","underlying_shares":9035},"source":{"system":"sec-edgar","filing":"0000950170-24-066146","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024066146/ownership.xml","form_type":"4"}},{"id":1499472,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-29T19:12:33.000Z","date":"2024-05-25","kind":"exercise","planned":false,"acquired":true,"shares":9035,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":108410,"source":{"system":"sec-edgar","filing":"0000950170-24-066146","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000095017024066146/ownership.xml","form_type":"4"}},{"id":1616793,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-02-27T19:56:59.000Z","date":"2024-02-25","kind":"exercise","planned":false,"acquired":false,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25, and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25, and November 25 of each year."}],"balance_after":45172,"derivative":{"underlying":"Common Stock","underlying_shares":9034},"source":{"system":"sec-edgar","filing":"0001209191-24-004039","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919124004039/doc4.xml","form_type":"4"}},{"id":1616792,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-02-27T19:56:59.000Z","date":"2024-02-25","kind":"exercise","planned":false,"acquired":true,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":99375,"source":{"system":"sec-edgar","filing":"0001209191-24-004039","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919124004039/doc4.xml","form_type":"4"}},{"id":1728865,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-11-28T19:01:32.000Z","date":"2023-11-25","kind":"exercise","planned":false,"acquired":false,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25, and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25, and November 25 of each year."}],"balance_after":54206,"derivative":{"underlying":"Common Stock","underlying_shares":9034},"source":{"system":"sec-edgar","filing":"0001209191-23-056838","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123056838/doc4.xml","form_type":"4"}},{"id":1728864,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-28T19:01:32.000Z","date":"2023-11-25","kind":"exercise","planned":false,"acquired":true,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":90341,"source":{"system":"sec-edgar","filing":"0001209191-23-056838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123056838/doc4.xml","form_type":"4"}},{"id":1794470,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-08-29T18:49:58.000Z","date":"2023-08-25","kind":"exercise","planned":false,"acquired":false,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25, and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25, and November 25 of each year."}],"balance_after":63240,"derivative":{"underlying":"Common Stock","underlying_shares":9034},"source":{"system":"sec-edgar","filing":"0001209191-23-047668","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123047668/doc4.xml","form_type":"4"}},{"id":1794469,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-29T18:49:58.000Z","date":"2023-08-25","kind":"exercise","planned":false,"acquired":true,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":81307,"source":{"system":"sec-edgar","filing":"0001209191-23-047668","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123047668/doc4.xml","form_type":"4"}},{"id":1802308,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-18T16:51:18.000Z","date":"2023-08-16","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option shall vest each month following the Vesting Commencement Date (as defined below), or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date. The Vesting Commencement Date is June 9, 2023."}],"balance_after":15000,"derivative":{"exercise_price":1.23,"expiration_date":"2033-08-16","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-046585","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123046585/doc4.xml","form_type":"4"}},{"id":1861106,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T18:28:46.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.5,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-036021","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123036021/doc4.xml","form_type":"4"}},{"id":1874230,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-30T20:15:38.000Z","date":"2023-05-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on May 25, 2024."}],"balance_after":30000,"derivative":{"exercise_price":1.82,"expiration_date":"2033-05-25","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-23-019460","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614936/000149315223019460/ownership.xml","form_type":"4"}},{"id":1877008,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-05-26T19:30:50.000Z","date":"2023-05-25","kind":"exercise","planned":false,"acquired":false,"shares":9035,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":72274,"derivative":{"underlying":"Common Stock","underlying_shares":9035},"source":{"system":"sec-edgar","filing":"0001209191-23-032709","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123032709/doc4.xml","form_type":"4"}},{"id":1877007,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-26T19:30:50.000Z","date":"2023-05-25","kind":"exercise","planned":false,"acquired":true,"shares":9035,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":72273,"source":{"system":"sec-edgar","filing":"0001209191-23-032709","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123032709/doc4.xml","form_type":"4"}},{"id":1987941,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-02-28T18:25:29.000Z","date":"2023-02-25","kind":"exercise","acquired":false,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":81309,"derivative":{"underlying":"Common Stock","underlying_shares":9034},"source":{"system":"sec-edgar","filing":"0001209191-23-013857","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123013857/doc4.xml","form_type":"4"}},{"id":1987940,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-02-28T18:25:29.000Z","date":"2023-02-25","kind":"exercise","acquired":true,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":63238,"source":{"system":"sec-edgar","filing":"0001209191-23-013857","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123013857/doc4.xml","form_type":"4"}},{"id":2102730,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-11-29T17:21:12.000Z","date":"2022-11-25","kind":"exercise","acquired":false,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":90343,"derivative":{"underlying":"Common Stock","underlying_shares":9034},"source":{"system":"sec-edgar","filing":"0001209191-22-058972","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122058972/doc4.xml","form_type":"4"}},{"id":2102729,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-11-29T17:21:12.000Z","date":"2022-11-25","kind":"exercise","acquired":true,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":54204,"source":{"system":"sec-edgar","filing":"0001209191-22-058972","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122058972/doc4.xml","form_type":"4"}},{"id":2147031,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-10-03T20:30:46.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":81000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to one-half of the total shares on September 30, 2023 and thereafter the remaining shares vest and become exercisable on September 30, 2024."}],"balance_after":81000,"derivative":{"exercise_price":2.16,"expiration_date":"2032-09-30","underlying":"Common Stock","underlying_shares":81000},"source":{"system":"sec-edgar","filing":"0001493152-22-027438","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614936/000149315222027438/ownership.xml","form_type":"4"}},{"id":2172160,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-08-29T21:16:28.000Z","date":"2022-08-25","kind":"exercise","acquired":false,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":99377,"derivative":{"underlying":"Common Stock","underlying_shares":9034},"source":{"system":"sec-edgar","filing":"0001209191-22-047949","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122047949/doc4.xml","form_type":"4"}},{"id":2172159,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-29T21:16:28.000Z","date":"2022-08-25","kind":"exercise","acquired":true,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":45170,"source":{"system":"sec-edgar","filing":"0001209191-22-047949","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122047949/doc4.xml","form_type":"4"}},{"id":2188400,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-11T19:01:48.000Z","date":"2022-08-10","kind":"grant","acquired":true,"shares":30282,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One twelfth (1/12th) of the shares subject to the Option shall vest each month following the Vesting Commencement Date (as defined below), on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), or if earlier one hundred percent (100%) of the shares subject to the Option shall vest on the date of the Company's next annual stockholder meeting, in each case subject to the Participant continuing to be a Service Provider (as defined in the Company's 2021 Equity Incentive Plan) through each such date. The Vesting Commencement Date is July 29, 2022."}],"balance_after":30282,"derivative":{"exercise_price":3.69,"expiration_date":"2032-08-10","underlying":"Common Stock","underlying_shares":30282},"source":{"system":"sec-edgar","filing":"0001209191-22-045494","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122045494/doc4.xml","form_type":"4"}},{"id":2236533,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T17:10:11.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option shall vest each month following the date of grant, or if earlier 100% of the shares subject to the option shall vest on the date of the Issuer's next annual stockholder meeting, in each case subject to the reporting person remaining a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":3.24,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-22-036012","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122036012/doc4.xml","form_type":"4"}},{"id":2254054,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-05-27T17:30:12.000Z","date":"2022-05-25","kind":"exercise","acquired":false,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":108411,"derivative":{"underlying":"Common Stock","underlying_shares":9034},"source":{"system":"sec-edgar","filing":"0001209191-22-032666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122032666/doc4.xml","form_type":"4"}},{"id":2254053,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-27T17:30:12.000Z","date":"2022-05-25","kind":"exercise","acquired":true,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":36136,"source":{"system":"sec-edgar","filing":"0001209191-22-032666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122032666/doc4.xml","form_type":"4"}},{"id":2366398,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-03-01T21:11:47.000Z","date":"2022-02-25","kind":"exercise","acquired":false,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":117445,"derivative":{"underlying":"Common Stock","underlying_shares":9034},"source":{"system":"sec-edgar","filing":"0001209191-22-014440","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122014440/doc4.xml","form_type":"4"}},{"id":2366397,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-01T21:11:47.000Z","date":"2022-02-25","kind":"exercise","acquired":true,"shares":9034,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":27102,"source":{"system":"sec-edgar","filing":"0001209191-22-014440","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122014440/doc4.xml","form_type":"4"}},{"id":2388375,"issuer":{"id":116797,"kind":"organization","name":"CONTRAFECT Corp","symbol":"CFRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options (Right to Buy)","published_at":"2022-02-17T18:18:58.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":500000,"price":3.33,"value":1665000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in equal quarterly installments with 6.25% of the total underlying shares vesting at the end of each quarter following the vesting commencement date, subject to continued service with the issuer through each vesting date."}],"balance_after":500000,"derivative":{"exercise_price":3.33,"expiration_date":"2032-02-15","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001209191-22-010972","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478069/000120919122010972/doc4.xml","form_type":"4"}},{"id":2493566,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-11-29T19:51:58.000Z","date":"2021-11-25","kind":"exercise","acquired":false,"shares":18068,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":126479,"derivative":{"underlying":"Common Stock","underlying_shares":18068},"source":{"system":"sec-edgar","filing":"0001209191-21-067047","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121067047/doc4.xml","form_type":"4"}},{"id":2493565,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-29T19:51:58.000Z","date":"2021-11-25","kind":"exercise","acquired":true,"shares":18068,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":18068,"source":{"system":"sec-edgar","filing":"0001209191-21-067047","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121067047/doc4.xml","form_type":"4"}},{"id":2611128,"issuer":{"id":6530,"kind":"organization","name":"Indaptus Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-08-06T21:00:32.000Z","date":"2021-08-04","kind":"grant","acquired":true,"shares":41000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable on August 4, 2022."}],"balance_after":41000,"derivative":{"exercise_price":8.87,"expiration_date":"2031-08-04","underlying":"Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0001493152-21-018909","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614936/000149315221018909/ownership.xml","form_type":"4"}},{"id":2750366,"issuer":{"id":116797,"kind":"organization","name":"CONTRAFECT Corp","symbol":"CFRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Options (Right to Buy)","published_at":"2021-04-13T21:47:29.000Z","date":"2021-04-08","kind":"grant","acquired":true,"shares":254000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in equal quarterly installments with 6.25% of the total underlying shares vesting at the end of each quarter following the vesting commencement date, subject to continued service with the issuer through each vesting date."}],"balance_after":254000,"derivative":{"exercise_price":4.31,"expiration_date":"2031-04-08","underlying":"Common Stock","underlying_shares":254000},"source":{"system":"sec-edgar","filing":"0001209191-21-026551","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478069/000120919121026551/doc4.xml","form_type":"4"}},{"id":2768368,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-30T20:11:18.000Z","date":"2021-03-26","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One thirty-sixth (1/36th) of the Shares subject to the Option shall vest on the one (1) month anniversary of March 1, 2021 (the \"Vesting Commencement Date\"), and one thirty-sixth (1/36th) of the Shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Therapeutics, Inc. 2021 Equity Incentive Plan) through each such date."}],"balance_after":135000,"derivative":{"exercise_price":8.74,"expiration_date":"2031-03-26","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001209191-21-023651","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121023651/doc4.xml","form_type":"4"}},{"id":3080029,"issuer":{"id":146542,"kind":"organization","name":"Intec Pharma Ltd.","symbol":"NTEC"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-07-17T20:39:17.000Z","date":"2020-07-15","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to one-third of the total shares on July 15, 2021 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through July 15, 2023."}],"balance_after":40000,"derivative":{"exercise_price":0.3075,"expiration_date":"2027-07-15","underlying":"Ordinary Shares","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001213900-20-017813","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614936/000121390020017813/ownership.xml","form_type":"4"}},{"id":3470335,"issuer":{"id":146542,"kind":"organization","name":"Intec Pharma Ltd.","symbol":"NTEC"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-07-02T20:40:34.000Z","date":"2019-06-28","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to one-third of the total shares on June 28, 2020 and thereafter the remaining shares vest and become exercisable in equal quarterly installments through June 28, 2022."}],"balance_after":20000,"derivative":{"exercise_price":4.858,"expiration_date":"2026-06-28","underlying":"Ordinary Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001213900-19-011972","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1614936/000121390019011972/ownership.xml","form_type":"4"}},{"id":3489036,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-14T20:19:06.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of June 13, 2020 or the day immediately prior to the company's 2020 annual meeting of shareholders."}],"balance_after":15000,"derivative":{"exercise_price":2.83,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-19-017036","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924319017036/doc4.xml","form_type":"4"}},{"id":3819206,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-09-11T20:49:26.000Z","date":"2018-09-07","kind":"sale","acquired":false,"shares":1810,"price":9.0007,"value":16291.267,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.03.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":213976,"source":{"system":"sec-edgar","filing":"0000899243-18-024194","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318024194/doc4.xml","form_type":"4"}},{"id":3822973,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-09-06T21:08:44.000Z","date":"2018-09-06","kind":"sale","acquired":false,"shares":3013,"price":9.0393,"value":27235.4109,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.17.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":215786,"source":{"system":"sec-edgar","filing":"0000899243-18-023938","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318023938/doc4.xml","form_type":"4"}},{"id":3822972,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-09-06T21:08:44.000Z","date":"2018-09-05","kind":"sale","acquired":false,"shares":9505,"price":9.123,"value":86714.115,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.26.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":218799,"source":{"system":"sec-edgar","filing":"0000899243-18-023938","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318023938/doc4.xml","form_type":"4"}},{"id":3862921,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-23T16:33:49.000Z","date":"2018-07-20","kind":"purchase","acquired":true,"shares":100,"price":23,"value":2300.0,"ownership":{"direct":true},"balance_after":100,"source":{"system":"sec-edgar","filing":"0001104659-18-046530","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000110465918046530/a4.xml","form_type":"4"}},{"id":3865402,"issuer":{"id":116417,"kind":"organization","name":"Rubius Therapeutics, Inc.","symbol":"RUBY"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-07-18T16:34:31.000Z","date":"2018-07-17","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in equal quarterly installments during the twelve quarters following the grant date."}],"balance_after":25000,"derivative":{"exercise_price":23,"expiration_date":"2028-07-16","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-18-045777","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1709401/000110465918045777/a4.xml","form_type":"4"}},{"id":3868461,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"STOCK OPTION (RIGHT TO BUY)","published_at":"2018-07-12T21:15:57.000Z","date":"2018-07-11","kind":"exercise","acquired":false,"shares":1010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested as to 25% of the shares on June 1, 2015.  The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter."}],"balance_after":797536,"derivative":{"exercise_price":0.71,"expiration_date":"2024-08-07","underlying":"COMMON STOCK","underlying_shares":1010},"source":{"system":"sec-edgar","filing":"0000899243-18-019814","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318019814/doc4.xml","form_type":"4"}},{"id":3868460,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-07-12T21:15:57.000Z","date":"2018-07-11","kind":"sale","acquired":false,"shares":1010,"price":9.0089,"value":9098.989,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.04.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":228304,"source":{"system":"sec-edgar","filing":"0000899243-18-019814","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318019814/doc4.xml","form_type":"4"}},{"id":3868459,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-07-12T21:15:57.000Z","date":"2018-07-11","kind":"exercise","acquired":true,"shares":1010,"price":0.71,"value":717.1,"ownership":{"direct":true},"balance_after":229314,"source":{"system":"sec-edgar","filing":"0000899243-18-019814","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318019814/doc4.xml","form_type":"4"}},{"id":3869898,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"STOCK OPTION (RIGHT TO BUY)","published_at":"2018-07-10T21:49:01.000Z","date":"2018-07-10","kind":"exercise","acquired":false,"shares":5989,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested as to 25% of the shares on June 1, 2015.  The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter."}],"balance_after":798546,"derivative":{"exercise_price":0.71,"expiration_date":"2024-08-07","underlying":"COMMON STOCK","underlying_shares":5989},"source":{"system":"sec-edgar","filing":"0000899243-18-019711","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/doc4.xml","form_type":"4"}},{"id":3869897,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"STOCK OPTION (RIGHT TO BUY)","published_at":"2018-07-10T21:49:01.000Z","date":"2018-07-09","kind":"exercise","acquired":false,"shares":10981,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested as to 25% of the shares on June 1, 2015.  The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter."}],"balance_after":804535,"derivative":{"exercise_price":0.71,"expiration_date":"2024-08-07","underlying":"COMMON STOCK","underlying_shares":10981},"source":{"system":"sec-edgar","filing":"0000899243-18-019711","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/doc4.xml","form_type":"4"}},{"id":3869896,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"STOCK OPTION (RIGHT TO BUY)","published_at":"2018-07-10T21:49:01.000Z","date":"2018-07-06","kind":"exercise","acquired":false,"shares":15366,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested as to 25% of the shares on June 1, 2015.  The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter."}],"balance_after":815516,"derivative":{"exercise_price":0.71,"expiration_date":"2024-08-07","underlying":"COMMON STOCK","underlying_shares":15366},"source":{"system":"sec-edgar","filing":"0000899243-18-019711","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/doc4.xml","form_type":"4"}},{"id":3869895,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-07-10T21:49:01.000Z","date":"2018-07-10","kind":"sale","acquired":false,"shares":5989,"price":9.0512,"value":54207.6368,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.23.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":228304,"source":{"system":"sec-edgar","filing":"0000899243-18-019711","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/doc4.xml","form_type":"4"}},{"id":3869894,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-07-10T21:49:01.000Z","date":"2018-07-10","kind":"exercise","acquired":true,"shares":5989,"price":0.71,"value":4252.19,"ownership":{"direct":true},"balance_after":234293,"source":{"system":"sec-edgar","filing":"0000899243-18-019711","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/doc4.xml","form_type":"4"}},{"id":3869893,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-07-10T21:49:01.000Z","date":"2018-07-09","kind":"sale","acquired":false,"shares":10981,"price":9.1386,"value":100350.9666,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.35.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":228304,"source":{"system":"sec-edgar","filing":"0000899243-18-019711","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/doc4.xml","form_type":"4"}},{"id":3869892,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-07-10T21:49:01.000Z","date":"2018-07-09","kind":"exercise","acquired":true,"shares":10981,"price":0.71,"value":7796.51,"ownership":{"direct":true},"balance_after":239285,"source":{"system":"sec-edgar","filing":"0000899243-18-019711","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/doc4.xml","form_type":"4"}},{"id":3869891,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-07-10T21:49:01.000Z","date":"2018-07-06","kind":"sale","acquired":false,"shares":15366,"price":9.144,"value":140506.704,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.23.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":228304,"source":{"system":"sec-edgar","filing":"0000899243-18-019711","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/doc4.xml","form_type":"4"}},{"id":3869890,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-07-10T21:49:01.000Z","date":"2018-07-06","kind":"exercise","acquired":true,"shares":15366,"price":0.71,"value":10909.86,"ownership":{"direct":true},"balance_after":243670,"source":{"system":"sec-edgar","filing":"0000899243-18-019711","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/doc4.xml","form_type":"4"}},{"id":3880262,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"STOCK OPTION (RIGHT TO BUY)","published_at":"2018-06-29T21:12:36.000Z","date":"2018-06-29","kind":"exercise","acquired":false,"shares":4496,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested as to 25% of the shares on June 1, 2015.  The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter."}],"balance_after":830882,"derivative":{"exercise_price":0.71,"expiration_date":"2024-08-07","underlying":"COMMON STOCK","underlying_shares":4496},"source":{"system":"sec-edgar","filing":"0000899243-18-018742","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/doc4.xml","form_type":"4"}},{"id":3880261,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"STOCK OPTION (RIGHT TO BUY)","published_at":"2018-06-29T21:12:36.000Z","date":"2018-06-28","kind":"exercise","acquired":false,"shares":21560,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested as to 25% of the shares on June 1, 2015.  The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter."}],"balance_after":835378,"derivative":{"exercise_price":0.71,"expiration_date":"2024-08-07","underlying":"COMMON STOCK","underlying_shares":21560},"source":{"system":"sec-edgar","filing":"0000899243-18-018742","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/doc4.xml","form_type":"4"}},{"id":3880260,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-06-29T21:12:36.000Z","date":"2018-06-29","kind":"sale","acquired":false,"shares":4496,"price":9.1004,"value":40915.3984,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.24.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":228304,"source":{"system":"sec-edgar","filing":"0000899243-18-018742","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/doc4.xml","form_type":"4"}},{"id":3880259,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-06-29T21:12:36.000Z","date":"2018-06-29","kind":"exercise","acquired":true,"shares":4496,"price":0.71,"value":3192.16,"ownership":{"direct":true},"balance_after":232800,"source":{"system":"sec-edgar","filing":"0000899243-18-018742","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/doc4.xml","form_type":"4"}},{"id":3880258,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-06-29T21:12:36.000Z","date":"2018-06-28","kind":"sale","acquired":false,"shares":21560,"price":9.1547,"value":197375.332,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.28.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":228304,"source":{"system":"sec-edgar","filing":"0000899243-18-018742","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/doc4.xml","form_type":"4"}},{"id":3880257,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-06-29T21:12:36.000Z","date":"2018-06-28","kind":"exercise","acquired":true,"shares":21560,"price":0.71,"value":15307.6,"ownership":{"direct":true},"balance_after":249864,"source":{"system":"sec-edgar","filing":"0000899243-18-018742","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/doc4.xml","form_type":"4"}},{"id":3881988,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"STOCK OPTION\n(RIGHT TO BUY)","published_at":"2018-06-28T01:06:10.000Z","date":"2018-06-27","kind":"exercise","acquired":false,"shares":16991,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested as to 25% of the shares on June 1, 2015.  The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter."}],"balance_after":856938,"derivative":{"exercise_price":0.71,"expiration_date":"2024-08-07","underlying":"COMMON STOCK","underlying_shares":16991},"source":{"system":"sec-edgar","filing":"0000899243-18-018520","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/doc4.xml","form_type":"4"}},{"id":3881987,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"STOCK OPTION\n(RIGHT TO BUY)","published_at":"2018-06-28T01:06:10.000Z","date":"2018-06-26","kind":"exercise","acquired":false,"shares":21224,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested as to 25% of the shares on June 1, 2015.  The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter."}],"balance_after":873929,"derivative":{"exercise_price":0.71,"expiration_date":"2024-08-07","underlying":"COMMON STOCK","underlying_shares":21224},"source":{"system":"sec-edgar","filing":"0000899243-18-018520","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/doc4.xml","form_type":"4"}},{"id":3881986,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"STOCK OPTION\n(RIGHT TO BUY)","published_at":"2018-06-28T01:06:10.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":16288,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vested as to 25% of the shares on June 1, 2015.  The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter."}],"balance_after":895153,"derivative":{"exercise_price":0.71,"expiration_date":"2024-08-07","underlying":"COMMON STOCK","underlying_shares":16288},"source":{"system":"sec-edgar","filing":"0000899243-18-018520","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/doc4.xml","form_type":"4"}},{"id":3881985,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-06-28T01:06:10.000Z","date":"2018-06-27","kind":"sale","acquired":false,"shares":16991,"price":9.0288,"value":153408.3408,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.16.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":228304,"source":{"system":"sec-edgar","filing":"0000899243-18-018520","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/doc4.xml","form_type":"4"}},{"id":3881984,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-06-28T01:06:10.000Z","date":"2018-06-27","kind":"exercise","acquired":true,"shares":16991,"price":0.71,"value":12063.61,"ownership":{"direct":true},"balance_after":245295,"source":{"system":"sec-edgar","filing":"0000899243-18-018520","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/doc4.xml","form_type":"4"}},{"id":3881983,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-06-28T01:06:10.000Z","date":"2018-06-26","kind":"sale","acquired":false,"shares":21224,"price":9.194,"value":195133.456,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.365.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":228304,"source":{"system":"sec-edgar","filing":"0000899243-18-018520","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/doc4.xml","form_type":"4"}},{"id":3881982,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-06-28T01:06:10.000Z","date":"2018-06-26","kind":"exercise","acquired":true,"shares":21224,"price":0.71,"value":15069.04,"ownership":{"direct":true},"balance_after":249528,"source":{"system":"sec-edgar","filing":"0000899243-18-018520","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/doc4.xml","form_type":"4"}},{"id":3881981,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-06-28T01:06:10.000Z","date":"2018-06-25","kind":"sale","acquired":false,"shares":26752,"price":9.2144,"value":246503.6288,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $9.08 to $9.52.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":228304,"source":{"system":"sec-edgar","filing":"0000899243-18-018520","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/doc4.xml","form_type":"4"}},{"id":3881980,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-06-28T01:06:10.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":16288,"price":0.71,"value":11564.48,"ownership":{"direct":true},"balance_after":255056,"source":{"system":"sec-edgar","filing":"0000899243-18-018520","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/doc4.xml","form_type":"4"}},{"id":3884703,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-06-23T01:11:54.000Z","date":"2018-06-22","kind":"sale","acquired":false,"shares":40057,"price":9.3557,"value":374761.2749,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.74.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":238768,"source":{"system":"sec-edgar","filing":"0000899243-18-017794","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318017794/doc4.xml","form_type":"4"}},{"id":3884702,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-06-23T01:11:54.000Z","date":"2018-06-21","kind":"sale","acquired":false,"shares":18987,"price":9.0638,"value":172094.3706,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.55.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":278825,"source":{"system":"sec-edgar","filing":"0000899243-18-017794","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318017794/doc4.xml","form_type":"4"}},{"id":3884701,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-06-23T01:11:54.000Z","date":"2018-06-20","kind":"sale","acquired":false,"shares":26492,"price":9.3255,"value":247051.146,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price.  The shares were sold in multiple transactions at per share prices ranging from $9.00 to $9.60.  The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":297812,"source":{"system":"sec-edgar","filing":"0000899243-18-017794","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318017794/doc4.xml","form_type":"4"}},{"id":3938334,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-05-10T20:44:46.000Z","date":"2018-05-09","kind":"sale","acquired":false,"shares":233,"price":9,"value":2097.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018."}],"balance_after":324304,"source":{"system":"sec-edgar","filing":"0000899243-18-012352","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318012352/doc4.xml","form_type":"4"}},{"id":4084588,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2018-01-31T02:03:02.000Z","date":"2018-01-30","kind":"grant","acquired":false,"shares":278000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on January 30, 2019.  The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":278000,"derivative":{"exercise_price":10.42,"expiration_date":"2028-01-29","underlying":"Common Stock","underlying_shares":278000},"source":{"system":"sec-edgar","filing":"0000899243-18-002335","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318002335/doc4.xml","form_type":"4"}},{"id":4089450,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2018-01-25T21:39:16.000Z","date":"2018-01-24","kind":"exercise","acquired":false,"shares":40241,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested as to 25% of the shares on June 1, 2015.  The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter."}],"balance_after":911441,"derivative":{"exercise_price":0.71,"expiration_date":"2024-08-07","underlying":"Common Stock","underlying_shares":40241},"source":{"system":"sec-edgar","filing":"0000899243-18-001894","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318001894/doc4.xml","form_type":"4"}},{"id":4089449,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2018-01-25T21:39:16.000Z","date":"2018-01-24","kind":"exercise","acquired":true,"shares":40241,"price":0.71,"value":28571.11,"ownership":{"direct":true},"balance_after":324537,"source":{"system":"sec-edgar","filing":"0000899243-18-001894","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924318001894/doc4.xml","form_type":"4"}},{"id":4250929,"issuer":{"id":116797,"kind":"organization","name":"CONTRAFECT Corp","symbol":"CFRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2017-07-26T16:48:51.000Z","date":"2017-07-25","kind":"purchase","acquired":true,"shares":400,"price":0.01,"value":4.0,"ownership":{"direct":true},"balance_after":400,"derivative":{"exercise_price":1.55,"exercise_date":"2017-07-25","expiration_date":"2022-07-25","underlying":"Common Stock, par value $0.0001 per share","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001209191-17-046319","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1478069/000120919117046319/doc4.xml","form_type":"4"}},{"id":4250928,"issuer":{"id":116797,"kind":"organization","name":"CONTRAFECT Corp","symbol":"CFRX"},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share","published_at":"2017-07-26T16:48:51.000Z","date":"2017-07-25","kind":"purchase","acquired":true,"shares":800,"price":1.24,"value":992.0,"ownership":{"direct":true},"balance_after":800,"source":{"system":"sec-edgar","filing":"0001209191-17-046319","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1478069/000120919117046319/doc4.xml","form_type":"4"}},{"id":4253753,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-07-20T20:36:12.000Z","date":"2017-07-18","kind":"exercise","acquired":false,"shares":100604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vested as to 25% of the shares on June 1, 2015.  The remainder of the shares have vested or will vest in 12 equal quarterly installments thereafter."}],"balance_after":951682,"derivative":{"exercise_price":0.71,"expiration_date":"2024-08-07","underlying":"Common Stock","underlying_shares":100604},"source":{"system":"sec-edgar","filing":"0000899243-17-018635","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924317018635/doc4.xml","form_type":"4"}},{"id":4253752,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2017-07-20T20:36:12.000Z","date":"2017-07-18","kind":"exercise","acquired":true,"shares":100604,"price":0.71,"value":71428.84,"ownership":{"direct":true},"balance_after":284296,"source":{"system":"sec-edgar","filing":"0000899243-17-018635","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924317018635/doc4.xml","form_type":"4"}},{"id":4478834,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":58090,"kind":"person","name":"Pomerantz Roger","position":1,"cik":"0001614936","reported_name":"Pomerantz Roger","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2017-01-27T22:51:10.000Z","date":"2017-01-26","kind":"grant","acquired":true,"shares":261000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on January 26, 2018.  The remainder of the shares will vest in 12 equal quarterly installments thereafter."}],"balance_after":261000,"derivative":{"exercise_price":9.89,"expiration_date":"2027-01-25","underlying":"Common Stock","underlying_shares":261000},"source":{"system":"sec-edgar","filing":"0000899243-17-002120","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1609809/000089924317002120/doc4.xml","form_type":"4"}}]}